PMC:7102591 / 14710-15967 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"463","span":{"begin":5,"end":12},"obj":"Chemical"},{"id":"469","span":{"begin":50,"end":58},"obj":"Species"},{"id":"470","span":{"begin":72,"end":79},"obj":"Chemical"},{"id":"471","span":{"begin":398,"end":405},"obj":"Chemical"},{"id":"472","span":{"begin":25,"end":34},"obj":"Disease"},{"id":"473","span":{"begin":47,"end":49},"obj":"Disease"},{"id":"483","span":{"begin":1080,"end":1083},"obj":"Gene"},{"id":"484","span":{"begin":764,"end":772},"obj":"Species"},{"id":"485","span":{"begin":1092,"end":1100},"obj":"Species"},{"id":"486","span":{"begin":702,"end":711},"obj":"Species"},{"id":"487","span":{"begin":805,"end":814},"obj":"Species"},{"id":"488","span":{"begin":1150,"end":1159},"obj":"Species"},{"id":"489","span":{"begin":621,"end":643},"obj":"Disease"},{"id":"490","span":{"begin":717,"end":727},"obj":"Disease"},{"id":"491","span":{"begin":1204,"end":1209},"obj":"Disease"}],"attributes":[{"id":"A469","pred":"tao:has_database_id","subj":"469","obj":"Tax:9606"},{"id":"A472","pred":"tao:has_database_id","subj":"472","obj":"MESH:D007239"},{"id":"A473","pred":"tao:has_database_id","subj":"473","obj":"MESH:D001172"},{"id":"A483","pred":"tao:has_database_id","subj":"483","obj":"Gene:7124"},{"id":"A484","pred":"tao:has_database_id","subj":"484","obj":"Tax:9606"},{"id":"A485","pred":"tao:has_database_id","subj":"485","obj":"Tax:9606"},{"id":"A486","pred":"tao:has_database_id","subj":"486","obj":"Tax:11309"},{"id":"A487","pred":"tao:has_database_id","subj":"487","obj":"Tax:11309"},{"id":"A488","pred":"tao:has_database_id","subj":"488","obj":"Tax:11309"},{"id":"A489","pred":"tao:has_database_id","subj":"489","obj":"MESH:D012141"},{"id":"A490","pred":"tao:has_database_id","subj":"490","obj":"MESH:D007239"},{"id":"A491","pred":"tao:has_database_id","subj":"491","obj":"MESH:D003643"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T189","span":{"begin":25,"end":34},"obj":"Disease"},{"id":"T190","span":{"begin":47,"end":49},"obj":"Disease"},{"id":"T192","span":{"begin":574,"end":584},"obj":"Disease"},{"id":"T193","span":{"begin":621,"end":643},"obj":"Disease"},{"id":"T194","span":{"begin":702,"end":711},"obj":"Disease"},{"id":"T195","span":{"begin":717,"end":727},"obj":"Disease"},{"id":"T196","span":{"begin":805,"end":814},"obj":"Disease"},{"id":"T197","span":{"begin":1150,"end":1159},"obj":"Disease"}],"attributes":[{"id":"A189","pred":"mondo_id","subj":"T189","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A190","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0005272"},{"id":"A191","pred":"mondo_id","subj":"T190","obj":"http://purl.obolibrary.org/obo/MONDO_0008383"},{"id":"A192","pred":"mondo_id","subj":"T192","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A193","pred":"mondo_id","subj":"T193","obj":"http://purl.obolibrary.org/obo/MONDO_0024355"},{"id":"A194","pred":"mondo_id","subj":"T194","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A195","pred":"mondo_id","subj":"T195","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A196","pred":"mondo_id","subj":"T196","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A197","pred":"mondo_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T111","span":{"begin":293,"end":294},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T112","span":{"begin":604,"end":611},"obj":"http://purl.obolibrary.org/obo/CLO_0009985"},{"id":"T113","span":{"begin":740,"end":741},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T114","span":{"begin":870,"end":871},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T120","span":{"begin":47,"end":49},"obj":"Chemical"}],"attributes":[{"id":"A120","pred":"chebi_id","subj":"T120","obj":"http://purl.obolibrary.org/obo/CHEBI_73810"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T78","span":{"begin":0,"end":12},"obj":"Sentence"},{"id":"T79","span":{"begin":13,"end":176},"obj":"Sentence"},{"id":"T80","span":{"begin":177,"end":446},"obj":"Sentence"},{"id":"T81","span":{"begin":447,"end":598},"obj":"Sentence"},{"id":"T82","span":{"begin":599,"end":684},"obj":"Sentence"},{"id":"T83","span":{"begin":685,"end":1009},"obj":"Sentence"},{"id":"T84","span":{"begin":1010,"end":1257},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T61","span":{"begin":47,"end":49},"obj":"Phenotype"},{"id":"T62","span":{"begin":621,"end":643},"obj":"Phenotype"}],"attributes":[{"id":"A61","pred":"hp_id","subj":"T61","obj":"http://purl.obolibrary.org/obo/HP_0001370"},{"id":"A62","pred":"hp_id","subj":"T62","obj":"http://purl.obolibrary.org/obo/HP_0011947"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}

{"project":"2_test","denotations":[{"id":"32205186-23192911-4826894","span":{"begin":169,"end":171},"obj":"23192911"},{"id":"32205186-29180125-4826895","span":{"begin":172,"end":174},"obj":"29180125"},{"id":"32205186-28298374-4826896","span":{"begin":214,"end":216},"obj":"28298374"},{"id":"32205186-19022409-4826897","span":{"begin":255,"end":257},"obj":"19022409"},{"id":"32205186-22796281-4826898","span":{"begin":261,"end":263},"obj":"22796281"},{"id":"32205186-29592917-4826899","span":{"begin":267,"end":269},"obj":"29592917"},{"id":"32205186-25975452-4826900","span":{"begin":442,"end":444},"obj":"25975452"},{"id":"32205186-23800448-4826901","span":{"begin":594,"end":596},"obj":"23800448"},{"id":"32205186-23256105-4826902","span":{"begin":1005,"end":1007},"obj":"23256105"}],"text":"4.3 bDMARDs\nThe risk of infection observed in RA patients treated with bDMARDs is generally considered slightly higher (from 1.5- up to 2-fold) compared with csDMARDs [27,54]. This evidence recurred in most RCTs [55] and observational registry studies [[56], [57], [58]] and was confirmed by a recent meta-analysis which showed that this risk is progressively increasing in relation to the use of bDMARDs at higher than recommended dosages [59]. Following the results of comparative metanalyses and real-life studies, abatacept is accepted as the safest bDMARD in terms of infectious risk [60,61].\nData focused on viral respiratory infections in bDMARD cohort are still very limited. The incidence of influenza-like infections observed in a cohort of 159 Italian patients treated with bDMARDs during the influenza season 2009–2010 was higher than the value reported in a wide sample of Italian population in the same period, even though no important complications or hospitalizations have been reported [62]. Overall, post-marketing experience is relatively reassuring that anti-TNF treated patients may not be at any specifically increased risk of influenza and that severe adverse outcomes, including death, do not appear to be exceedingly frequent [63]."}